Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Complarate vs Actemra in Healthy Volunteers
NCT06481202Phase 1Completed
- Sponsor
- Generium
- Start
- Apr 2022
- Primary completion
- Jun 2022
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Generium. Primary endpoints: Area under the plasma concentration versus time curve at Day 43 and Peak Plasma Concentration at Day 43. Started Apr 2022; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06481202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06481202.